Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 9/20 | 0.39 |
| ▸ | JAK1 | P23458 | 9/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105218 | 0.88 | USP2 (0.45) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL388054 | 0.84 | USP2 (0.46) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL5751932 | 0.81 | USP2 (0.44) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL1118079 | 0.79 | USP2 (0.47) | USP2SMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL849908 | 0.79 | USP2 (0.47) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL17632152 | 0.78 | USP2 (0.41) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL386890 | 0.78 | SMN1; SMN2 (0.41) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL1118226 | 0.77 | USP2 (0.49) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL1973674 | 0.77 | USP2 (0.49) | USP2SMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL2887782 | 0.77 | USP2 (0.49) | USP2SMN1; SMN2MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-2009006-A1 | UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | TORAY INDUSTRIES, INC. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | USP2 99/4885SMN1; SMN2 349/4885MEN1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.